文献速递造血干细胞移植与细胞治疗白血病

全骨髓及淋巴照射联合环磷酰胺与依托泊苷预处理方案治疗复发或难治性急性白血病的II期试验

Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2026-05-18

这项单中心、开放标签、II期试验评估了全骨髓及淋巴照射(2000 cGy)联合大剂量环磷酰胺与依托泊苷作为异基因造血细胞移植前预处理方案,用于16-60岁复发或难治性急性白血病患者。106例患者接受治疗,2年无进展生存率为34%(95%CI 25-43%),最常见的3-4级不良事件为血细胞减少(91%)和代谢紊乱(78%)。

要点

  • 全骨髓及淋巴照射2000 cGy联合大剂量依托泊苷和环磷酰胺可安全实施。
  • 2年无进展生存率为34%(95%CI 25-43%)。
  • 3-4级不良事件以血细胞减少(91%)和代谢紊乱(78%)最常见。

核心结论

  • 全骨髓及淋巴照射2000 cGy联合大剂量依托泊苷和环磷酰胺预处理方案安全性可接受,并伴有令人鼓舞的2年无进展生存率。

研究设计与样本

  • 单中心、开放标签、II期试验,含初始6例安全性导入,在美国开展,纳入16-60岁复发或难治性急性髓系或淋巴细胞白血病患者,共106例接受预处理和移植。

主要发现

  • 全组2年无进展生存率估计为34%(95%CI 25-43%)。
  • 安全性导入期6例患者均未出现不可接受的毒性。
  • 最常见的3-4级不良事件为血细胞减少96例(91%)、代谢紊乱83例(78%)、口腔黏膜炎45例(42%)、腹泻25例(24%)、恶心21例(20%)和手足综合征11例(10%)。
  • 1例患者死于归因于预处理方案的肝窦阻塞综合征。

关键数值与推荐

  • 全骨髓及淋巴照射于第-9至-5天给予,骨髓和淋巴结剂量为2000 cGy。
  • 依托泊苷60 mg/kg于第-4天给药,环磷酰胺100 mg/kg于第-2天给药。
  • 移植物抗宿主病预防采用他克莫司联合西罗莫司。

临床怎么用

  • 该预处理方案可用于复发或难治性急性白血病患者异基因造血细胞移植前,需关注血细胞减少和代谢紊乱等毒性。

局限性

  • 单中心、开放标签、II期设计,样本量有限,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total marrow and lymphoid irradiation delivers augmented doses of radiation to the bone marrow and lymph nodes while maintaining low doses to vital organs. We aimed to assess the effectiveness of combining total marrow and lymphoid irradiation (2000 cGy to bone marrow and lymph nodes) with high-dose cyclophosphamide and etoposide as a conditioning regimen before allogeneic haematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute leukaemia. METHODS: This single-centre, open-label, phase 2 trial with an initial six-patient safety lead-in, conducted in the USA, enrolled patients aged between 16 and 60 years with relapsed or refractory acute myeloid leukaemia or acute lymphoblastic leukaemia. Total marrow and lymphoid irradiation was given on days -9 to -5, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Bone marrow or peripheral blood stem cells from sibling or matched or one allele mismatched unrelated donors were infused on day 0. Graft versus host disease prophylaxis consisted of tacrolimus and sirolimus. The primary endpoint for the initial safety lead-in segment was toxicity and for the phase 2 study was 2-year progression-free survival. All patients who began treatment were included in the analysis. This trial is registered with ClinicalTrials.gov, NCT02094794, and is closed to accrual. FINDINGS: Between May 9, 2014, and Mar 5, 2024, 107 patients were enrolled and screened for eligibility. One did not meet eligibility criteria (uncontrolled cytomegalovirus). 106 received conditioning radiation and HCT per protocol. Median follow-up was 1·8 years (IQR 0·6-3·0) for all patients and 3·1 years (2·1-4·9) for patients who were alive at last contact. None of the six patients in the safety lead-in experienced unacceptable toxicity. 49 (46%) of 106 patients were female and 57 (54%) were male. 72 (68%) of patients were White and 22 (21%) were Asian or Pacific Islander. The 2-year estimate of progression-free survival in all patients was 34% (95% CI 25-43%). The most common grade 3-4 adverse events were cytopenias 96 (91%), metabolic disorders 83 (78%), oral mucositis 45 (42%), diarrhoea 25 (24%), nausea 21 (20%), and palmar-plantar erythrodysesthesia syndrome 11 (10%). One patient died of sinusoidal obstruction syndrome attributed to the conditioning regimen. INTERPRETATION: Adverse events were few, probably due to organ sparing by total marrow and lymphoid irradiation. Total marrow and lymphoid irradiation 2000 cGy could be safely delivered in combination with high-dose etoposide and cyclophosphamide. The regimen was associated with encouraging 2-year progression-free survival rates. FUNDING: National Institutes of Health and Accuray.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Stein A, Wang Y, Malki MMA, et al. Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial. Lancet Haematol. 2026. PMID: 42150590. doi:10.1016/S2352-3026(26)00014-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。